Fwd: Diagnostic significance of 'atypia' in instrumented versus voided urine specimens.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: Diagnostic significance of 'atypia' in instrumented versus voided urine specimens.
To: mesothelioma77@gmail.com


[1]Cancer. 2008 Jun 11;
Kapur U, Venkataraman G, Wojcik EM

BACKGROUND.: Urine cytology plays an important role in monitoring patients with a history of urothelial carcinoma. Because it is difficult to reliably discriminate artifacts induced by instrumentation, inflammation, or therapy those of from malignant cells, many of these specimens are categorized as atypical. The objective of the current study was to study the prevalence and significance of atypical urine cytology with regard to the effect of instrumentation and prior biopsy. METHODS.: All urine cytology cases seen during a 4-year period (2001-2004) with a diagnosis of atypical urothelial cells (AU) were obtained from the cytopathology computer database. In all cases with available surgical follow-up, the following data were extracted: total number and type of urine specimen, the primary histologic diagnosis, and follow-up histologic diagnosis. RESULTS.: In all, 1653 voided and 3502 instrumented urine specimens were examined. A diagnosis of AU was rendered in 115 (6.9%) of the voided urine specimens and in 277 (7.9%) of the instrumented specimens. Follow-up histology was available in 70 cases, including 55 instrumented and 15 voided urine specimens. A nonbenign follow-up diagnosis was observed in 18 of 55 (32.7%) cases in the instrumented group and in 7 of 15 (46.6%) cases in the voided group. Voided urine was marginally associated with a worse subsequent biopsy diagnosis (Pexact Monte Carlo = .09) CONCLUSIONS.: An AU diagnosis is more predictive of a subsequent adverse biopsy diagnosis in voided urine specimens compared with instrumented urines. In the absence of a benchmark for the atypia rate, it is prudent to keep the atypia rate low to keep it more meaningful. This important category should be used by the pathologist to convey concern and recognize the difficulty in interpretation of specimens that may require close follow-up. Cancer (Cancer Cytopathol) 2008. (c) 2008 American Cancer Society.



___
Source: http://www.hubmed.org/display.cgi?uids=18548527
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Effects of antisense RNA targeting of ODC and AdoMetDC on the synthesis of polyamine synthesis and cell growth in prostate cancer cells using a prostatic androgen-dependent promoter in adenovirus.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: Effects of antisense RNA targeting of ODC and AdoMetDC on the synthesis of polyamine synthesis and cell growth in prostate cancer cells using a prostatic androgen-dependent promoter in adenovirus.
To: mesothelioma77@gmail.com


[1]Prostate. 2008 Jun 11;
Li W, Liu X, Wang W, Sun H, Hu Y, Lei H, Liu G, Gao Y

PURPOSE: This study was designed to investigate the use of a prostatic androgen-dependent promoter to mediate antisense targeting of ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC) and its effects on the synthesis of polyamine. We also examined the potential of this construct for prostate cancer therapy. METHODS: pADxsi-PSES-AdoMetDC-ODC-PolyA AV was constructed and used to infect various cancer cell lines, including LNCaP, HT-29, H1299, HepG2. The effects of pADxsi-PSES-AdoMetDC-ODC-PolyA AV on the expression of ODC and AdoMetDC, in addition to the cell cycle, apoptosis and p21 levels, were analyzed through Western blotting and cytometry. A Matrigel invasion assay was used to analyze the effects of the recombinant virus on tumor cell invasion. The effect on polyamine content was also determined, and the relationship between inhibition of cellular ODC and AdoMetDC and decreases in polyamine were also investigated using a polyamine recovery assay. RESULTS: Treatment with pADxsi-PSES-AdoMetDC-ODC-PolyA at an MOI of 90 significantly inhibited the proliferation of LNCaP cells, which could not be recovered through the addition of exogenous putrescine. The expression of ODC and AdoMetDC was also reduced, as was the polyamine content. The G1 phase of LNCaP cells was delayed, but no increase in apoptosis was detected. The down-regulation of ODC and AdoMetDC led to increased p21 expression. CONCLUSIONS: The pADxsi-PSES-AdoMetDC-ODC-PolyA AV specifically inhibited the expression of ODC and AdoMetDC and the synthesis of polyamine, while it induced p21 expression, resulting in cell growth arrest in the G1 phase in prostate cancer cells but not in other cells. Prostate (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18548481
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Impact of Body Mass Index on Perioperative Outcomes in Patients Undergoing Major Intra-abdominal Cancer Surgery.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: Impact of Body Mass Index on Perioperative Outcomes in Patients Undergoing Major Intra-abdominal Cancer Surgery.
To: mesothelioma77@gmail.com


[1]Ann Surg Oncol. 2008 Jun 12;
Mullen JT, Davenport DL, Hutter MM, Hosokawa PW, Henderson WG, Khuri SF, Moorman DW

BACKGROUND: Obesity is an increasingly common serious chronic health condition. We sought to determine the impact of body mass index (BMI) on perioperative outcomes in patients undergoing major intra-abdominal cancer surgery. METHODS: A prospective, multi-institutional, risk-adjusted cohort study of patients undergoing major intra-abdominal cancer surgery was performed from the 14 university hospitals participating in the Patient Safety in Surgery Study of the National Surgical Quality Improvement Program (NSQIP). Demographic, clinical, and intraoperative variables and 30-day morbidity and mortality were prospectively collected in standardized fashion. Analysis of variance, Bonferroni multiple comparisons of means tests, and multivariable logistic regression analysis were performed. RESULTS: We identified 2258 patients who underwent esophagectomy (n = 29), gastrectomy (n = 223), hepatectomy (n = 554), pancreatectomy (n = 699), or low anterior resection/proctectomy (n = 753). Patients were stratified by National Institutes of Health (NIH)-defined BMI obesity class, with 573 (25.4%) patients classified as obese (BMI > 30 kg/m(2)). There were no differences in mean work relative value units, total time of operation, or length of stay amongst the BMI classes. After adjusting for other risk factors, obesity was not a risk factor for death or major complications but was a risk factor for wound complications. The risk of postoperative death was greatest in underweight patients (odds ratio [OR] 5.24; 95% confidence interval [CI] 1.7-16.2). CONCLUSION: In patients undergoing major intra-abdominal cancer surgery, obesity is not a risk factor for postoperative mortality or major complications. Importantly, underweight patients have a fivefold increased risk of postoperative mortality, perhaps a consequence of their underlying nutritional status.



___
Source: http://www.hubmed.org/display.cgi?uids=18548313
--
 
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients.
To: mesothelioma77@gmail.com


[1]Cancer Immun. 2008; 8: 10
Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R

We assessed the immunological status of stage III and IV head and neck squamous cell carcinoma (HNSCC) patients and age-matched healthy individuals. In HNSCC patients, the total leukocyte count was lower and the proliferating ability of PBMCs against phytohemagglutinin (PHA) was significantly downregulated. These cells showed lower expression of the early activation marker CD69. Within this PBMC population, the proportion of CD4+, CD8+ T cells, CD3- CD56+, CD16+ NK cells and CD3+ CD56+ NK-T cells was seriously downregulated. However, the proportion of CD4+ CD25+ Foxp3+ regulatory T cells having suppressor function was upregulated. Other immune cells, like CD14+ monocytes/macrophages and CD20+ B cells, were also fewer in number, although this difference was not statistically significant. Assessment of the cytokine secretory status of PBMCs revealed suppressed levels of Th1 cytokines (IFN-gamma, IL-12 and TNF-alpha) and elevated secretion of Th2 cytokines (IL-4 and IL-10) for HNSCC PBMCs whereas just the opposite was seen for PBMCs from healthy individuals. Dysregulation in the profile of immunocompetent cells and cytokine secretion was reflected in the suppressed cytotoxic function of HNSCC PBMCs, as tested on KB (oral cancer), MCF7 (breast cancer), COLO205 (colon cancer), Jurkat (T cell leukemia), K562 (erythroleukemia) and U937 (monocytic lymphoma) cell lines. The observed decreased cytotoxicity of HNSCC PBMCs may be due to the downregulated expression of cytotoxic molecules (perforin, granzymeB and FasL) in HNSCC PBMCs. Assessment of the extent of immune dysfunction might help design immunotherapeutic protocols by incorporating any agent having immunomodulatory function.



___
Source: http://www.hubmed.org/display.cgi?uids=18547033
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Imaging Surveillance of the Breast in a Patient Diagnosed with Scleroderma after Breast-Conserving Surgery and Radiotherapy.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: Imaging Surveillance of the Breast in a Patient Diagnosed with Scleroderma after Breast-Conserving Surgery and Radiotherapy.
To: mesothelioma77@gmail.com


[1]Breast J. 2008 Jun 10;
Seale M, Koh W, Henderson M, Drummond R, Cawson J

Collagen vascular disease (CVD), particularly scleroderma, is a contraindication to radiation therapy because of increased risk of fibrosis. We report a patient with early stage breast cancer diagnosed with scleroderma after breast-conserving surgery and radiation. She developed marked breast fibrosis, rendering mammographic, sonographic, and clinical surveillance ineffective. She has subsequently been followed with magnetic resonance imaging (MRI) of the breast. We illustrate this case and review the literature relating to CVD and radiation therapy. MRI may be a suitable surveillance method in this situation.



___
Source: http://www.hubmed.org/display.cgi?uids=18547380
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Internet-Based Survey Evaluating Use of Pain Medications and Attitudes of Radiation Oncology Patients Toward Pain Intervention.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 13, 2008 at 11:19 PM
Subject: Internet-Based Survey Evaluating Use of Pain Medications and Attitudes of Radiation Oncology Patients Toward Pain Intervention.
To: mesothelioma77@gmail.com


[1]Int J Radiat Oncol Biol Phys. 2008 Jun 9;
Simone CB, Vapiwala N, Hampshire MK, Metz JM

PURPOSE: Pain is a common symptom among cancer patients, yet many patients do not receive adequate pain management. Few data exist quantifying analgesic use by radiation oncology patients. This study evaluated the causes of pain in cancer patients and investigated the reasons patients fail to receive optimal analgesic therapy. METHODS AND MATERIALS: An institutional review board-approved, Internet-based questionnaire assessing analgesic use and pain control was posted on the OncoLink (available at www.oncolink.org) Website. Between November 2005 and April 2006, 243 patients responded. They were predominantly women (73%), white (71%), and educated beyond high school (67%) and had breast (38%), lung (6%), or ovarian (6%) cancer. This analysis evaluated the 106 patients (44%) who underwent radiotherapy. RESULTS: Of the 106 patients, 58% reported pain from their cancer treatment, and 46% reported pain directly from their cancer. The pain was chronic in 51% and intermittent in 33%. Most (80%) did not use medication to manage their pain. Analgesic use was significantly less in patients with greater education levels (11% vs. 36%, p = 0.002), with a trend toward lower use by whites (16% vs. 32%, p = 0.082) and women (17% vs. 29%, p = 0.178). The reasons for not taking analgesics included healthcare provider not recommending medication (87%), fear of addiction or dependence (79%), and inability to pay (79%). Participants experiencing pain, but not taking analgesics, pursued alternative therapies for relief. CONCLUSIONS: Many radiation oncology patients experience pain from their disease and cancer treatment. Most study participants did not use analgesics because of concerns of addiction, cost, or failure of the radiation oncologist to recommend medication. Healthcare providers should have open discussions with their patients regarding pain symptoms and treatment.



___
Source: http://www.hubmed.org/display.cgi?uids=18547743
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Rudolph's perplexing legacy - Herald Tribune

---------- Forwarded message ----------
From: asbestos cancer - Live Search News <rssfwd@rssfwd.com>
Date: Sun, Jun 8, 2008 at 10:31 PM
Subject: Rudolph's perplexing legacy - Herald Tribune
To: mesothelioma77@gmail.com


SARASOTA — Paul Rudolph came to Sarasota in 1948 as a young architect with a master's degree from Harvard and left 10 years later to become dean of the School of Art and Architecture at Yale. From that influential post he became the most ...

Sun, 08 Jun 2008 13:53:00 GMT

___
Source: http://www.heraldtribune.com/article/20080608/NEWS/223993615/0/newssitemap
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Benefit small from lung cancer screening method (Reuters via Yahoo! News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Benefit small from lung cancer screening method (Reuters via Yahoo! News)
To: mesothelioma77@gmail.com


A high-tech X-ray called a spiral CT scan may help reduce lung cancer deaths in smokers and former smokers, but only reduces their overall risk of premature death by 4 percent, researchers reported on Tuesday.

Tue, 10 Jun 2008 21:28:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=128df378m/*http%3A//news.yahoo.com/s/nm/20080610/hl_nm/cancer_lung_screening_dc_1
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Jun 10;
Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, Cortinovis D, Conte GD, Ceribelli A, Bearz A, Salamina S, De Vincenzo F, Cappuzzo F, Marangolo M, Torri V, Santoro A

The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. In this study, pooled data from two phase II trials of pemetrexed and carboplatin (PC) as first-line therapy were retrospectively analysed for comparisons between age groups. Patients received pemetrexed 500 mg m(-2) and carboplatin AUC 5 mg ml(-1) min(-1) intravenously every 21 days with standard vitamin supplementation. Elderly patients were defined as those >/=70 years old. A total of 178 patients with an ECOG performance status of /=70 years (27%). Grade 3-4 haematological toxicity was slightly worse in >/=70 vs

___
Source: http://www.hubmed.org/display.cgi?uids=18542071
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

[

Fwd: Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Jun 10;
Sørensen JB, Frank H, Palshof T

The aim was to evaluate the activity of cisplatin and vinorelbine in previously untreated, inoperable patients having histologically verified malignant pleural mesothelioma (MPM), normal organ function, and performance status 0-2. Treatment was vinorelbine 25 mg m(-2) i.v. weekly and cisplatin 100 mg m(-2) i.v. every 4 weeks with hydration and standard prophylactic antiemetic treatment. Patients gave written informed consent. Characteristics of 54 consecutive patients were: males 85%, epithelial subtype 74%, IMIG stages III and IV 35 and 46%, performance status 0, 1, and 2, 26, 69, and 6%, and median age 63 years (31-78 years). CTC grade 3 or 4 toxicity occurred with respect to leukocytopenia (48% of patients, grade 4 in 13%), nausea (13%), neurotoxicity (11%), nephrotoxicity (4%), and other toxicities (9%). There were no toxic deaths. The median number of cycles was four. The fraction of patients alive at 1-, 2-, and 3-years were 61, 31, and 4%, respectively, and median survival and median time to progression were 16.8 months (0.5 to 46.4 +months) and 7.2 months (1.6 to 40.6 + months). There were two CRs and 14 PRs (response rate 29.6%). Cisplatin and intravenous vinorelbine is a highly active regimen in MPM with a response rate and survival comparable to the most active regimens so far reported.British Journal of Cancer advance online publication, 10 June 2008; doi:10.1038/sj.bjc.6604421 www.bjcancer.com.



___
Source: http://www.hubmed.org/display.cgi?uids=18542078
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
To: mesothelioma77@gmail.com


[1]Cancer. 2008 Jun 9;
Hainsworth JD, Spigel DR, Barton J, Farley C, Schreeder M, Hon J, Greco FA

BACKGROUND.: The purpose of the current study was to evaluate the efficacy and toxicity of weekly bortezomib in the treatment of patients with recurrent/refractory multiple myeloma. METHODS.: A total of 40 patients with multiple myeloma who had received either 1 or 2 previous treatment regimens were treated with bortezomib at a dose of 1.6 mg/m(2) intravenously for 4 consecutive weeks, followed by 1 week without treatment. Responses were measured using International Myeloma Working Group criteria. RESULTS.: Twenty-two patients (55%; 95% confidence interval, 40%-70%) achieved objective responses to treatment, with a median response duration of 16 months. The median progression-free survival for all patients was 9.6 months, with a 1-year progression-free survival rate of 39%. The 1-year and 2-year overall survival rates were 75% and 51%, respectively. Weekly bortezomib was generally well tolerated; grade 3/4 (using the National Cancer Institute Common Toxicity Criteria [version 3.0]) neutropenia (13%), thrombocytopenia (20%), fatigue (15%), diarrhea (13%), and neuropathy (10%) were experienced by a minority of patients. CONCLUSIONS.: In the current study, a schedule of weekly bortezomib was found to be effective and well tolerated in patients with previously treated multiple myeloma. Although the response rate and duration appear comparable to those achieved with twice-weekly bortezomib, the relative efficacy of these 2 schedules cannot be determined definitively on the basis of this phase 2 study. A weekly schedule of bortezomib is a reasonable option for patients who have logistic difficulties receiving a twice-weekly schedule, and is an attractive schedule for incorporation into combination regimens. Cancer 2008. (c) 2008 American Cancer Society.



___
Source: http://www.hubmed.org/display.cgi?uids=18543319
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Is there an optimal comorbidity index for prostate cancer?

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Is there an optimal comorbidity index for prostate cancer?
To: mesothelioma77@gmail.com


[1]Cancer. 2008 Jun 9;
Cai T, Bartoletti R





___
Source: http://www.hubmed.org/display.cgi?uids=18543325
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Metastatic breast cancer cells colonize and degrade three-dimensional osteoblastic tissue in vitro.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Metastatic breast cancer cells colonize and degrade three-dimensional osteoblastic tissue in vitro.
To: mesothelioma77@gmail.com


[1]Clin Exp Metastasis. 2008 Jun 10;
Dhurjati R, Krishnan V, Shuman LA, Mastro AM, Vogler EA

Metastatic breast cancer cells (BCs) colonize a mineralized three-dimensional (3D) osteoblastic tissue (OT) grown from isolated pre-osteoblasts for up to 5 months in a specialized bioreactor. Sequential stages of BC interaction with OT include BC adhesion, penetration, colony formation, and OT reorganization into "Indian files" paralleling BC colonies, heretofore observed only in authentic pathological cancer tissue. BCs permeabilize OT by degrading the extra-cellular collagenous matrix (ECM) in which the osteoblasts are embedded. OT maturity (characterized by culture age and cell phenotype) profoundly affects the patterns of BC colonization. BCs rapidly form colonies on immature OT (higher cell/ECM ratio, osteoblastic phenotype) but fail to completely penetrate OT. By contrast, BCs efficiently penetrate mature OT (lower cell/ECM ratio, osteocytic phenotype) and reorganize OT. BC colonization provokes a strong osteoblast inflammatory response marked by increased expression of the pro-inflammatory cytokine IL-6. Furthermore, BCs inhibit osteoblastic bone formation by down-regulating synthesis of collagen and osteocalcin. Results strongly suggest that breast cancer disrupts the process of osteoblastic bone formation, in addition to upregulating osteoclastic bone resorption as widely reported. These observations may help explain why administration of bisphosphonates to humans with osteolytic metastases slows lesion progression by inhibiting osteoclasts but does not bring about osteoblast-mediated healing.



___
Source: http://www.hubmed.org/display.cgi?uids=18543066
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: The Nottingham Prognostic Index for Invasive Carcinoma of the Breast.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: The Nottingham Prognostic Index for Invasive Carcinoma of the Breast.
To: mesothelioma77@gmail.com


[1]Pathol Oncol Res. 2008 Jun 10;
Lee AH, Ellis IO

A useful prognostic factor in breast cancer has key roles, including identification of a group of patients whose prognosis is so good they do not require further treatment, such as adjuvant systemic therapy, after local surgery, and secondly a group with a poor prognosis for whom additional treatment would be appropriate. To be of clinical use, prognostic factors must show a wide separation in the outcome of the groups identified and select adequate numbers in each group. No single prognostic factor in invasive carcinoma of the breast satisfies all these criteria. However, the Nottingham prognostic index (NPI), which combines nodal status, tumour size and histological grade, does satisfy these criteria. The NPI has been validated by further studies in Nottingham and by studies in several other countries. Predictive factors, such as oestrogen receptor and HER-2 status, predict whether a tumour is likely to respond to a treatment, and are complimentary to prognostic factors. The NPI can be used in combination with predictive factors to select patients for systemic adjuvant treatments. There is the potential to improve the NPI by inclusion of other factors, such as vascular invasion, but any such alterations would require further validation.



___
Source: http://www.hubmed.org/display.cgi?uids=18543079
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Physical activity as a negative modulator of estrogen-induced breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Physical activity as a negative modulator of estrogen-induced breast cancer.
To: mesothelioma77@gmail.com


[1]Cancer Causes Control. 2008 Jun 10;
Coyle YM

Physical activity is a protective factor for breast cancer. Exposure to estrogen is an important determinant of breast cancer risk and exercise reduces estrogen levels, with the level of evidence being stronger for post-menopausal women. Possible mechanisms for estrogen induced breast cancer include increased breast epithelial cell proliferation, the metabolism of estrogen to genotoxic metabolites, such as DNA-adducts, and the silencing of tumor suppressor genes (TSGs) that have been implicated in breast carcinogenesis by inducing gene promoter hypermethylation, which is potentially reversible. Animal studies suggest that physical activity decreases breast tumor growth by promoting changes in cellular proliferation and apoptosis. Human studies provide some support for exercise producing favorable changes in estrogen metabolism that may lead to reduced breast epithelial cell proliferation. No studies have been performed to determine whether exercise decreases the accumulation of estrogen metabolite DNA-adducts in breast tissue. However, research supports the hypothesis that physical activity reduces promoter hypermethylation of TSGs implicated in breast carcinogenesis by lowering circulating estrogen levels. Thus, further research is necessary to clarify the mechanisms that relate to physical activity as a negative modulator of breast cancer risk to develop meaningful guidelines for the use of physical activity in breast cancer prevention.



___
Source: http://www.hubmed.org/display.cgi?uids=18543069
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Pattern of metastatic spread in triple-negative breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Pattern of metastatic spread in triple-negative breast cancer.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 Jun 10;
Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA

Purpose The prognosis of women with triple-negative breast cancers (defined as cancers that are estrogen receptor-negative, progesterone receptor-negative and HER2/neu negative) is poor, compared to women with other subtypes of breast cancer. It is proposed that the underlying difference in recurrence rates may be explained in part by different routes of metastatic spread. Experimental design We studied a cohort of 1608 patients diagnosed with breast cancer, diagnosed between January 1987 and December 1997 at Women's College Hospital in Toronto. Triple-negative breast cancers were defined as those that were estrogen receptor-negative, progesterone receptor-negative and HER2/neu-negative. We compared the incidence rates of metastatic spread to bone and to other (non-bone) organs in women with triple-negative and other forms of breast cancer. Results Of the 1,608 patients, 180 (11.2%) had triple-negative breast cancer. The 1608 women were followed for a median of 9.0 years (range 0.1-19 years). Compared to other patients, those with triple-negative breast cancer had an increased likelihood of distant recurrence over the study period (adjusted hazard ratio (HR) 1.9; 95% CI: 1.5-2.5, P

___
Source: http://www.hubmed.org/display.cgi?uids=18543098
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
To: mesothelioma77@gmail.com


[1]Cancer. 2008 Jun 9;
Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH

BACKGROUND.: Although deletion of the derivative chromosome 9 (der 9; del-der 9) carries a poor prognosis in patients with chronic myeloid leukemia (CML) who are treated with hydroxyurea or interferon, its significance in patients on imatinib mesylate (IM) therapy is debated. METHODS.: In the current study, the authors used a locus-specific indicator breakpoint cluster region/receptor tyrosine kinase (BCR/ABL) probe to evaluate the significance of del-der 9 in 163 patients with CML who had fluorescence in situ hybridization (FISH) results available. Serial changes in BCR/ABL fusion transcript levels also were monitored by using messenger RNA (mRNA) quantitative polymerase chain reaction (PCR). RESULTS.: Of 163 patients, 22 (13.5%) had del-der 9 before commencing IM therapy. No differences were noted in the time to hematologic response (P = .598), major cytogenetic response (CyR) (P = .281), complete CyR (P = .883), major molecular response (MoR) (P = .125), or complete MoR (P = .834). In addition, the times to loss of response (LOR) (P = .974), treatment failure (P = .455; including primary hematologic or cytogenetic resistance and LOR), transformation-free survival (P = .276), and dose escalation of IM (P = .816) did not differ significantly between patients with and without del-der 9. The results of serial BCR/ABL mRNA quantitative PCR revealed similar patterns of BCR/ABL fusion gene reduction between the 2 groups. CONCLUSIONS.: The presence of del-der 9 in patients with CML did not influence 1) the response to IM therapy in terms of hematologic response, CyR, or MoR; 2) LOR; 3) treatment failure; 4) progression to accelerated phase/blast crisis; or 5) time to dose escalation of IM. Therefore, the authors concluded that the detection of del-der 9 does not have an impact on the current management of patients with CML who are receiving IM therapy. Cancer 2008. (c) 2008 American Cancer Society.



___
Source: http://www.hubmed.org/display.cgi?uids=18543309
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions.
To: mesothelioma77@gmail.com


[1]Mol Carcinog. 2008 Jun 9;
García P, Manterola C, Araya JC, Villaseca M, Guzmán P, Sanhueza A, Thomas M, Alvarez H, Roa JC

Gallbladder carcinoma (GBC) is a highly malignant neoplasm and represents the leading cause of cancer death in Chilean women. In order to determine the potential role of promoter methylation in gallbladder carcinogenesis, we investigated the frequency of this epigenetic mechanism by methylation-specific polymerase chain reaction (MSP) in 35 chronic cholecystitis (CC, separated according to the presence or absence of metaplasia), 19 early cancers (mucosa or muscularis propia invasion) and 48 advanced carcinomas with invasion of the gallbladder subserosa (25 cases) and serosa (23 cases). We examined 14 genes and observed an increase of multigenic methylation during tumoral progression which was not significantly associated with the patient's age. Four genes (DAPK1, DLC1, TIMP3, and RARbeta2) displayed a progressive increase in their methylation status from CC without metaplasia to advanced carcinoma invading the serosa layer (P

___
Source: http://www.hubmed.org/display.cgi?uids=18543280
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells.
To: mesothelioma77@gmail.com


[1]Oncogene. 2008 Jun 9;
Ueki T, Nishidate T, Park JH, Lin ML, Shimo A, Hirata K, Nakamura Y, Katagiri T

To investigate the detailed molecular mechanism of mammary carcinogenesis and discover novel therapeutic targets, we previously analysed gene expression profiles of breast cancers. We here report characterization of a significant role of DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein) in mammary carcinogenesis. Semiquantitative RT-PCR and northern blot analyses confirmed upregulation of DTL/RAMP in the majority of breast cancer cases and all of breast cancer cell lines examined. Immunocytochemical and western blot analyses using anti-DTL/RAMP polyclonal antibody revealed cell-cycle-dependent localization of endogenous DTL/RAMP protein in breast cancer cells; nuclear localization was observed in cells at interphase and the protein was concentrated at the contractile ring in cytokinesis process. The expression level of DTL/RAMP protein became highest at G(1)/S phases, whereas its phosphorylation level was enhanced during mitotic phase. Treatment of breast cancer cells, T47D and HBC4, with small-interfering RNAs against DTL/RAMP effectively suppressed its expression and caused accumulation of G(2)/M cells, resulting in growth inhibition of cancer cells. We further demonstrate the in vitro phosphorylation of DTL/RAMP through an interaction with the mitotic kinase, Aurora kinase-B (AURKB). Interestingly, depletion of AURKB expression with siRNA in breast cancer cells reduced the phosphorylation of DTL/RAMP and decreased the stability of DTL/RAMP protein. These findings imply important roles of DTL/RAMP in growth of breast cancer cells and suggest that DTL/RAMP might be a promising molecular target for treatment of breast cancer.Oncogene advance online publication, 9 June 2008; doi:10.1038/onc.2008.186.



___
Source: http://www.hubmed.org/display.cgi?uids=18542055
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Anthropometric factors and breast cancer risk among urban and rural women in South India: a multicentric case-control study.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Anthropometric factors and breast cancer risk among urban and rural women in South India: a multicentric case-control study.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Jun 10;
Mathew A, Gajalakshmi V, Rajan B, Kanimozhi V, Brennan P, Mathew BS, Boffetta P

Breast cancer (BC) incidence in India is approximately twice as high in urban women than in rural women, among whom we investigated the role of anthropometric factors and body size. The study was conducted at the Regional Cancer Centre, Trivandrum, and in three cancer hospitals in Chennai during 2002-2005. Histologically confirmed cases (n=1866) and age-matched controls (n=1873) were selected. Anthropometric factors were measured in standard ways. Information on body size at different periods of life was obtained using pictograms. Odds ratios (OR) of BC were estimated through logistic regression modelling. Proportion of women with body mass index (BMI)>25.0 kg/m(2), waist size >85 cm and hip size >100 cm was significantly higher among urban than rural women. Risk was increased for waist size >85 cm (pre-menopausal: OR=1.24, 95% CI: 0.96-1.62; post-menopausal: 1.61, 95% CI: 1.22-2.12) and hip size >100 cm (pre-menopausal: OR=1.47, 95% CI: 1.05-2.06; post-menopausal 2.42, 95% CI: 1.72-3.41). Large body size at age 10 (OR=1.75, 95% CI: 1.01-3.03) and increased BMI (OR=1.33, 95% CI: 1.05-1.69 for 25.0-29.9 kg/m(2) and OR=1.56, 95% CI: 1.03-2.35 for 30+ kg/m(2)) were associated with pre-menopausal BC risk. Our data support the hypotheses that increased anthropometric factors are risk factors of BC in India.British Journal of Cancer advance online publication, 10 June 2008; doi:10.1038/sj.bjc.6604423 www.bjcancer.com.



___
Source: http://www.hubmed.org/display.cgi?uids=18542077
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Somatically Acquired Hypomethylation of IGF2 in Breast and Colorectal Cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Somatically Acquired Hypomethylation of IGF2 in Breast and Colorectal Cancer.
To: mesothelioma77@gmail.com


[1]Hum Mol Genet. 2008 Jun 9;
Ito Y, Koessler T, Ibrahim AE, Rai S, Vowler SL, Abu-Amero S, Silva AL, Maia AT, Huddleston JE, Uribe-Lewis S, Woodfine K, Jagodic M, Nativio R, Dunning A, Moore G, Klenova E, Bingham S, Pharoah PD, Brenton JD, Beck S, Sandhu MS, Murrell A

The imprinted Insulin-like growth factor 2 gene (IGF2) is expressed predominantly from the paternal allele. Loss of imprinting (LOI) associated with hypomethylation at the promoter proximal sequence (DMR0) of the IGF2 gene was proposed as a predisposing constitutive risk biomarker for colorectal cancer. We used pyrosequencing to assess whether IGF2 DMR0 methylation is either present constitutively prior to cancer or whether it is acquired tissue-specifically after the onset of cancer. DNA samples from tumour tissues and matched non-tumour tissues from 22 breast and 42 colorectal cancer patients as well as peripheral blood samples obtained from Colorectal cancer patients (SEARCH (n= case 192, controls 96)), breast cancer patients (ABC (n= case 364, controls 96)) and the European Prospective Investigation of Cancer (EPIC-Norfolk (n=breast 228, colorectal 225, controls 895)), were analysed. The EPIC samples were collected two to five years prior to diagnosis of breast or colorectal cancer. IGF2 DMR0 methylation levels in tumours were lower than matched non-tumour tissue. Hypomethylation of DMR0 was detected in breast (33%) and colorectal (80%) tumour tissues with a higher frequency than LOI indicating that methylation levels are a better indicator of cancer than LOI. In the EPIC population the prevalence of IGF2 DMR0 hypomethylation was 9.5% and this correlated with increased age not cancer risk. Thus IGF2 DMR0 hypomethylation occurs as an acquired tissue-specific somatic event rather than a constitutive innate epimutation. These results indicate that IGF2 DMR0 hypomethylation has diagnostic potential for colon cancer rather than value as a surrogate biomarker for constitutive LOI.



___
Source: http://www.hubmed.org/display.cgi?uids=18541649
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jun 11, 2008 at 11:46 PM
Subject: Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
To: mesothelioma77@gmail.com


[1]Endocr Relat Cancer. 2008 Jun 9;
Day J, Tutill H, Purohit A, Reed M

17beta-Hydroxysteroid dehydrogenases (17beta-HSDs) are enzymes which are responsible for reduction or oxidation of hormones, fatty acids and bile acids in vivo, regulating the amount of the active form which is available to bind to its cognate receptor. All require NAD(P)(H) for activity. Fifteen 17beta-HSDs have been identified to date, and with one exception, 17beta-HSD Type 5 (17beta-HSD5), an aldo-keto reductase (AKR), they are all short chain dehydrogenases / reductases (SDRs), although overall homology between the enzymes is low. Although named as 17beta-HSDs, reflecting the major redox activity at the 17beta-position of the steroid backbone, the activities of these fourteen enzymes vary, with several of the 17beta-HSDs able to reduce and/or oxidise multiple substrates at various positions. These activities are involved in the progression of a number of diseases, including those related to steroid metabolism. Despite the success of inhibitors of steroidogenic enzymes in the clinic, such as those of aromatase and steroid sulphatase, the development of inhibitors of 17beta-HSDs is at a relatively early stage, as at present none have yet reached clinical trials. However, many groups are now working on inhibitors specific for several of these enzymes for the treatment of steroid-dependent diseases, including breast and prostate cancer, and endometriosis, with demonstrable efficacy in in vivo disease models. In this review the recent advances in the validation of these enzymes as targets for the treatment of these diseases, with emphasis on 17beta-HSD1, 3, and 5, the development of specific inhibitors, the models used for their evaluation, and their progress towards the clinic will be discussed.



___
Source: http://www.hubmed.org/display.cgi?uids=18541621
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Cost-effectiveness of Oral Clodronate Compared with Oral Ibandronate, Intravenous Zoledronate or Intravenous Pamidronate in Breast Cancer Patients.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 8, 2008 at 10:31 PM
Subject: Cost-effectiveness of Oral Clodronate Compared with Oral Ibandronate, Intravenous Zoledronate or Intravenous Pamidronate in Breast Cancer Patients.
To: mesothelioma77@gmail.com


[1]J Int Med Res. 2008 May-Jun; 36(3): 400-13
Paterson A, McCloskey E, Redzepovic J, Ott I, Gust R

This study aimed to identify the effects of different bisphosphonates in reducing skeletal-related events, and to determine whether there are any differences in their cost-effectiveness, taking into account their efficacy, safety profile and administration routes. A systematic literature search of databases, such as PubMed and the Cochrane Controlled Trials Register, supplemented by the latest congress abstracts from meetings of the European Hematology Association and the American Society of Clinical Oncology was conducted up to November 2006. Important references in reviews published by peer-reviewed journals were also taken into consideration. Our base-case cost-effectiveness analysis for Germany and the UK showed cost savings for oral clodronate therapy compared with other bisphosphonate therapies. In Germany, costs per patient of treatment with oral clodronate were euro1092.38, euro2360.40 and euro2500.29 less than with oral ibandronate, intravenous pamidronate and intravenous zoledronate, respectively. The UK results were similar, the costs per patient of treatment with oral clodronate being euro841.79, euro2989.99 and euro3669.19 less than with oral ibandronate, intravenous pamidronate and intravenous zoledronate, respectively.



___
Source: http://www.hubmed.org/display.cgi?uids=18534121
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Inhalable Form Of Gene-therapy Takes Aim At Lung Cancer And Inflammatory Lung Disease (Science Daily)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: Inhalable Form Of Gene-therapy Takes Aim At Lung Cancer And Inflammatory Lung Disease (Science Daily)
To: mesothelioma77@gmail.com


A new inhalable form of gene therapy -- based on technology recognized in the 2006 Nobel medicine prize, shows increasing promise for treating lung cancer, infectious diseases and inflammatory lung disease, scientists have concluded after an exhaustive review of worldwide research on the topic.

Mon, 09 Jun 2008 14:39:58 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=121kkudqk/*http%3A//www.sciencedaily.com/releases/2008/06/080609091913.htm
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Newman 'dying of lung cancer' (Perth Now)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: Newman 'dying of lung cancer' (Perth Now)
To: mesothelioma77@gmail.com


LEGENDARY screen actor Paul Newman has been diagnosed with terminal lung cancer, according to reports in the United States.

Tue, 10 Jun 2008 03:19:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12it2bgll/*http%3A//news.com.au/perthnow/story/0,21498,23840822-948,00.html?from=public_rss
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Misamis Oriental solon dies of lung cancer (ABS-CBNNEWS.com)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: Misamis Oriental solon dies of lung cancer (ABS-CBNNEWS.com)
To: mesothelioma77@gmail.com


A congressman in Misamis Oriental succumbed to lung cancer on Saturday. Rep. Danilo Lagbas Sr. of the 1st District died at the St. Luke's Medical Center in Quezon City. He was 56.

Mon, 09 Jun 2008 06:50:28 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11smjcdrp/*http%3A//www.abs-cbnnews.com/storypage.aspx?StoryId=121138
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Paul Newman 'battling lung cancer'

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: Paul Newman 'battling lung cancer'
To: mesothelioma77@gmail.com

Paul Newman. Photo / Reuters Paul Newman reportedly has lung cancer. The Butch Cassidy and the Sundance Kid actor has been suffering from the potentially fatal disease for several months and just weeks ago had ...

Tue, 10 Jun 2008 11:13:17 GMT

---

Source: http://www.nzherald.co.nz/category/story.cfm?c_id=200&objectid=10515531&ref=rss
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Venture Investors Find Comfort in Health Care

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: Venture Investors Find Comfort in Health Care
To: mesothelioma77@gmail.com

After several years of languishing in the shadows of blockbuster Internet start-up companies, deals involving health-care and medical companies are making a comeback.

Tue, 10 Jun 2008 09:32:19 GMT

---

Source: http://online.wsj.com/article/SB121297780236456277.html?mod=SmallBusinessFinancing_more_articles
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: The Fabulous Report: Perfect jeans for smaller waist, bigger hips - Fort Lauderdale Sun-Sentinel

---------- Forwarded message ----------
From: asbestos cancer - Live Search News <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:24 AM
Subject: The Fabulous Report: Perfect jeans for smaller waist, bigger hips - Fort Lauderdale Sun-Sentinel
To: mesothelioma77@gmail.com


Although you think it is only you, the truth is: Everyone has trouble finding jeans that fit. And those who don't are genetic freaks who just happen to have the same proportions as a fit model ... which is nothing to brag about since — these days ...

Sun, 08 Jun 2008 00:53:00 GMT

___
Source: http://www.sun-sentinel.com/features/lifestyle/sfl-fashionfabulous08sbjun08,0,193657.story
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Inhalable form of gene-therapy takes aim at lung cancer and inflammatory lung disease (PhysOrg)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: Inhalable form of gene-therapy takes aim at lung cancer and inflammatory lung disease (PhysOrg)
To: mesothelioma77@gmail.com


A new inhalable form of gene therapy — based on technology recognized in the 2006 Nobel medicine prize, shows increasing promise for treating lung cancer, infectious diseases and inflammatory lung disease, scientists have concluded after an exhaustive review of worldwide research on the topic. Their report is scheduled for the June 2 issue of ACS' Molecular Pharmaceutics.

Mon, 09 Jun 2008 17:02:04 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11d9cc7ev/*http%3A//www.physorg.com/news132234633.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: 09.06.2008 - DJ HUGIN NEWS/Epigenomics Successfully Completes Clinical Study in Lung Cancer Diagnosis (4investors)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: 09.06.2008 - DJ HUGIN NEWS/Epigenomics Successfully Completes Clinical Study in Lung Cancer Diagnosis (4investors)
To: mesothelioma77@gmail.com


Berlin, Germany, and Seattle, WA, USA, June 9, 2008 - Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular diagnostics company focusing on the development and commercialization of products for cancer based on DNA methylation, today announced that it successfully completed a clinical study in its lung cancer program.

Mon, 09 Jun 2008 07:01:41 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12aue1l27/*http%3A//www.4investors.de/php_fe/indexdow.php?sektion=dowjones&ID=67060
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Paul Newman fighting lung cancer (Daily Telegraph)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: Paul Newman fighting lung cancer (Daily Telegraph)
To: mesothelioma77@gmail.com


NEW photos have emerged of ill Hollywood star Paul Newman, which show signs of how his lung cancer battle have taken its toll on him.

Mon, 09 Jun 2008 14:00:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=1300vq3ia/*http%3A//www.news.com.au/dailytelegraph/story/0,22049,23840675-5001026,00.html?from=public_rss
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Long wait is norm for Owens Corning asbestos claimants

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: Long wait is norm for Owens Corning asbestos claimants
To: mesothelioma77@gmail.com

OC trust jammed by numbers of cases Twelve months after first submitting claims for clients with asbestos-related diseases, attorney Jimmy Rodgers is waiting to collect from the Owens Corning/Fibreboard ...

Tue, 10 Jun 2008 11:41:48 GMT

---

Source: http://toledoblade.com/apps/pbcs.dll/article?AID=/20080610/BUSINESS03/806100354/-1/BUSINESS
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Swayze returns to work but Newman forced to quit

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 10, 2008 at 8:23 AM
Subject: Swayze returns to work but Newman forced to quit
To: mesothelioma77@gmail.com

Paul Newman reportedly has lung cancer. The Butch Cassidy and the Sundance Kid actor has been suffering from the potentially fatal disease for several months and just weeks ago had to pull out of directing a ...

Tue, 10 Jun 2008 07:03:33 GMT

---

Source: http://www.theage.com.au/news/people/swayze-returns-to-work-but-newman-forced-to-quit/2008/06/10/1212863597715.html
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 8, 2008 at 10:31 PM
Subject: Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.
To: mesothelioma77@gmail.com


[1]Ann Nucl Med. 2008 May; 22(4): 245-50
Nishiyama Y, Yamamoto Y, Kimura N, Ishikawa S, Sasakawa Y, Ohkawa M

OBJECTIVE: The objective of this study was to retrospectively evaluate whether delayed additional F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging can improve the certainty of this modality in evaluating lymph node metastasis in patients with non-small-cell lung cancer (NSCLC). METHODS: Eighty-three patients with NSCLC were examined. FDG-PET imaging (whole body) was performed at 1-h (early) post-FDG injection and repeated 2 h (delayed) after injection only in the thoracic area. The PET images were evaluated qualitatively for regions of focally increased metabolism. If a lymph node was visible on the PET image, the semi-quantitative analysis using the standardized uptake value (SUV) was determined for both early and delayed images (SUV(early) and SUV(delayed), respectively). Retention index (RI) was then calculated on the basis of the following equation: (SUV(delayed) - SUV(early)) x 100/SUV(early). The RI value of more than 0% was taken to be the PET criterion for malignancy. RESULTS: For early and delayed PET, sensitivities for lymph node staging were 54% and 62%, respectively, specificities were 89% for both, and accuracies were 78% and 81%, respectively. The results of combined delayed PET and RI showed a sensitivity of 62%, specificity of 96%, and accuracy of 86%. CONCLUSIONS: Dual-time-point FDG-PET (combined delayed PET and RI) showed better (although not statistically significant) specificity, positive predictive value, and accuracy than early or delayed PET alone for lymph node staging in NSCLC.



___
Source: http://www.hubmed.org/display.cgi?uids=18535874
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [Postoperative inconveniences after breast cancer surgery.]

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 8, 2008 at 10:31 PM
Subject: [Postoperative inconveniences after breast cancer surgery.]
To: mesothelioma77@gmail.com


[1]Ugeskr Laeger. 2008 Jun 2; 170(23): 2032-2034
Gärtner R, Callesen T, Kroman N, Kehlet H

The most common postoperative inconveniences after breast cancer surgery are pain, nausea and vomiting, which contribute to reduced patient satisfaction, prolonged hospital stays and delayed courses of rehabilitation. This article summarizes the literature regarding available procedure-specific evidence for prophylactic nausea, vomiting and pain treatment supported by transferable evidence from similar types of surgery. We propose a prophylactic combination of Dexametason, Ondansteron, Paracetamol, Celecoxib, Gabapentin and Detromethorphan as future treatment.



___
Source: http://www.hubmed.org/display.cgi?uids=18534168
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 8, 2008 at 10:31 PM
Subject: Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.
To: mesothelioma77@gmail.com


[1]Breast. 2008 Jun 3;
Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y, Sugimura H

Neoadjuvant chemotherapy (NAC) is now a relatively standard treatment for breast carcinoma. However, some tumors are known to develop resistance to chemotherapies. We investigated whether the status of estrogen receptor (ER), progesterone receptor (PR) and Her-2 expressions in breast cancer cases prior to NAC could be changed after NAC. We used immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods. No differences were found in ER or Her-2 status, but a significant difference was found in PR status. Changes in Her-2 status were suspected in four specimens after NAC (3+ to 1+ for 3 patients, and 1+ to 3+ for one patient) according to the IHC results. However, in all four of these cases, FISH of the resections showed no change. When IHC indicates a change in Her-2 expression after NAC, FISH is recommended.



___
Source: http://www.hubmed.org/display.cgi?uids=18534850
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 8, 2008 at 10:31 PM
Subject: Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer.
To: mesothelioma77@gmail.com


[1]Ann Oncol. 2008 Jun 5;
Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A

BACKGROUND: Women with triple-negative (TN) breast cancer are at increased risk of distant metastases and have reduced survival versus other breast cancer patients. Relative survival of women with TN breast cancer who develop brain metastases is unknown. METHODS: Patients with breast cancer who developed brain metastases at our institution from 1993 to 2006 were reviewed. Four survival time intervals were compared in patients with TN disease and those with non-TN disease: initial diagnosis to distant metastases, distant metastases to brain metastases, brain metastases to death, and overall diagnosis to death. RESULTS: One hundred and eighteen patients were identified. Fifty-one (50%) of 103 were estrogen receptor positive, 26 (39%) of 67 were human epidermal growth factor receptor 2 positive, and 20 (22%) of 91 were TN. Survival times were shorter for TN patients, with overall survival of 26 months in TN patients versus 49 months for non-TN patients. In TN patients, time to development of distant metastases, brain metastases, and death after brain metastases was shorter than in non-TN patients. CONCLUSION: Patients with TN disease were more likely to develop distant metastases earlier than non-TN patients, developed brain metastases sooner, and had shorter overall survival.



___
Source: http://www.hubmed.org/display.cgi?uids=18534964
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [Multimodal treatment of pain and nausea in breast cancer surgery.]

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 8, 2008 at 10:31 PM
Subject: [Multimodal treatment of pain and nausea in breast cancer surgery.]
To: mesothelioma77@gmail.com


[1]Ugeskr Laeger. 2008 Jun 2; 170(23): 2035-2038
Gärtner R, Kroman N, Callesen T, Kehlet H

INTRODUCTION: Every year 4000 women in Denmark undergo surgery for breast cancer. According to published literature approximately 50% suffer from post-operative nausea and vomiting (PONV) and moderate pain. No national guidelines are available regarding the treatment or prevention of pain and PONV associated with surgery for these patients. MATERIALS AND METHODS: 116 consecutive patients scheduled for breast cancer surgery were prospectively scored according to pain, PONV and sedation after being introduced to a combined evidence-based, empiric multimodal opioid-sparing prevention and treatment regime consisting of Paracetamol, Celecoxib, Dextromethorphan, Gabapetin, Dexamethason and Ondansetron. RESULTS: In the recovery room, 75% of the patients scored either no or light pain at rest compared to 68% under mobilization. In the department, 94% of the patients scored no or light pain at rest as well as under mobilization on the evening of the operation and the next morning. Morphine consumption in the recovery room was, on average, 2 mg per patient. Only 1.5% of the patients were given morphine in the department. Five patients were troubled by light PONV, one by moderate PONV and another suffered from severe PONV and vomiting resistant to treatment. Upon arrival at the recovery 15% of the patients were in a state of moderate to severe sedation. This number was 1.5% 75 minutes later. CONCLUSION: It is possible with a multimodal opioid-sparing prevention and treatment regime for pain and PONV to gain optimal postoperative pain and nausea control without significant problems with respect to sedation.



___
Source: http://www.hubmed.org/display.cgi?uids=18534169
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Jab1 is a target of EGFR signaling in ER-alpha negative breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 8, 2008 at 10:31 PM
Subject: Jab1 is a target of EGFR signaling in ER-alpha negative breast cancer.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res. 2008 Jun 5; 10(3): R51
Wang J, Barnes RO, West NR, Olson M, Chu JE, Watson PH

ABSTRACT: INTRODUCTION: c-Jun activation domain binding protein-1 (Jab1) is a multifunctional signaling protein that has previously been shown to be a master regulator of a poor prognostic gene signature in invasive breast cancer and to mediate the action of S100A7. Since epidermal growth factor receptor (EGFR), like S100A7, is often expressed in ER-alpha negative breast cancer, we set out to investigate the role of Jab1 in mediating EGFR signaling, another facet of the ER-alpha negative phenotype. METHODS: MDA-MB-231 and MDA-MB-468 ER-alpha negative/EGFR positive cell lines were assessed for localization of Jab1 and levels of downstream genes by immunofluorescence and nuclear protein extract assay following treatment with epidermal growth factor (EGF) and extracellular signal-regulated kinase (ERK) pathway inhibitor. A cohort of 424 human breast tumors was also assessed by immunohistochemistry. RESULTS: EGF treatment of cell lines resulted in increased Jab1 nuclear expression. This effect was inhibited by the ERK pathway inhibitor, PD98059. EGF treatment was also associated with co-localization of pERK and Jab1, as well as regulation of the Jab1 downstream target gene, p27. When Jab1 activity was knocked down, p27 levels were restored to pre-EGF treatment level. Analysis of EGFR and Jab1 expression in a cohort of invasive breast tumors by tissue microarray and immunohistochemistry confirmed a relationship between EGFR and increased nuclear Jab1 within the ER-alpha negative subset (n=154, p=0.019). The same association was also confirmed for S100A7 and Jab1 (p=0.036), and high Jab1 nuclear expression was most frequent in tumors that were positive for both EGFR and S100A7 (p=0.004). CONCLUSIONS: Jab1 is a target of EGFR signaling in ER-alpha negative cell lines and breast tumors and therefore may be a common, central factor and potential therapeutic target for important cell signaling pathways in ER-alpha negative breast cancer.



___
Source: http://www.hubmed.org/display.cgi?uids=18534028
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Cancer of the esophagus and stomach.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 7, 2008 at 2:25 AM
Subject: Cancer of the esophagus and stomach.
To: mesothelioma77@gmail.com


[1]Mayo Clin Proc. 2008 Jun; 83(6): 712-22
Khushalani N

Upper gastrointestinal tumors involving the esophagus and the stomach are a serious public health problem worldwide. The West has seen a dramatic increase in the incidence of gastroesophageal cancers in the past 2 decades. Although Barrett esophagus has been well characterized, the exact pathway to developing frank malignancy remains undefined. Current treatments for locoregional disease include surgery, chemotherapy, radiation therapy, or some combination thereof. Clinical trials are currently investigating biologic agents that target signaling pathways in carcinogenesis. Whether this research translates into an improved therapeutic index remains to be seen. This review provides a comprehensive update to physicians and residents who contribute to the care of these patients. Studies in the English language were identified searching PubMed (January 1, 1980, through February 29, 2008) using the terms esophagus, gastric, carcinoma, adenocarcinoma, squamous cell, radiation, chemotherapy, surgery, esophagectomy, and targeted therapy.



___
Source: http://www.hubmed.org/display.cgi?uids=18533089
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: An integrated system to deliver impulsive radiation force and to image induced transient strain for monitoring focused ultrasound surgery.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 7, 2008 at 2:25 AM
Subject: An integrated system to deliver impulsive radiation force and to image induced transient strain for monitoring focused ultrasound surgery.
To: mesothelioma77@gmail.com


[1]J Acoust Soc Am. 2008 May; 123(5): 3793
Berry G, Bamber J, Ma Y, Rivens I, Ter Haar G

Thermal coagulation of tissue causes an approximate three-fold increase in stiffness, which can be easily detected by various elasticity imaging methods. Advantages have been reported, for application to breast cancer diagnosis, of an elasticity imaging method that applies a highly localised transient stress deep within the tissue using a low frequency focused ultrasound radiation force impulse, and uses relatively high frequency echo imaging to measure the transient strain generated in the tissue placed between the transducers. In this paper we describe a new system that implements this concept using a focused ultrasound surgical transducer to apply the transient (

___
Source: http://www.hubmed.org/display.cgi?uids=18532178
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Clinical experiences with extracorporeal Ultrasound-guided high-intensity focused ultrasound treatment for cancer patients.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 7, 2008 at 2:25 AM
Subject: Clinical experiences with extracorporeal Ultrasound-guided high-intensity focused ultrasound treatment for cancer patients.
To: mesothelioma77@gmail.com


[1]J Acoust Soc Am. 2008 May; 123(5): 2995
Wu F

Noninvasive, image-guided tumour thermal ablation with extracorporeal high-intensity focused ultrasound (HIFU) has received increasing interest in the treatment of patients with solid tumours. Since December 1997, an extracorporeal ultrasound-guided HIFU system (Mode-JC, Haifu Technology Co. Ltd., Chongqing, China) has been used to treat approximately 10,000 patients with solid tumours in China, including those of liver, breast, bone, kidney, pancreas, soft tissue, and uterus. The same device has been recently introduced into the UK, Italy, Japan, and South Korea, and so far, more than 1,000 patients have received HIFU treatment outside China. The purpose of this article is to introduce our clinical experiences using extracorporeal, ultrasound-guided HIFU ablation for solid tumours. Five-year follow-up data are observed in patients with primary liver cancer, breast cancer, and osteosarcoma. Among patients treated with HIFU, an extremely low major complication rate is observed. In conclusion, our clinical studies indicate that HIFU treatment is a safe, effective, and feasible modality in the treatment of cancer patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18529307
--
 , Inc

 

Fwd: The Individualization of Cancer Therapy: The Unexpected Role of p53.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 7, 2008 at 2:25 AM
Subject: The Individualization of Cancer Therapy: The Unexpected Role of p53.
To: mesothelioma77@gmail.com


[1]Trans Am Clin Climatol Assoc. 2006; 117: 85-101
Hait WN, Yang JM

Our laboratory discovered that p53 can regulate the sensitivity to cancer therapies by affecting three critical aspects of cancer pharmacology: 1). The expression of drug targets; 2). the access of drugs to intracellular targets; and the response to DNA damage. We review the effects of p53 on antimicrotubule drugs through transcriptional regulation of MAP4 and stathmin (Oncoprotein 18). These two p53-regulated proteins control microtubule dynamics, regulate the sensitivity to taxanes and vinca alkaloids by changing the polymerization dynamics of tubulin and affecting the binding of drugs to microtubules. We found that overexpression of MAP4 increased microtubule polymerization and increased taxane binding and sensitivity. Overexpression of stathmin, a microtubule destabilizer, virtually abolished cellular taxane binding and increased resistance by over 1000-fold. Yet, despite an increased binding of vinca alkaloids to stathmin transfectants, we did not observe increased drug sensitivity. This was explained, at least in part, by a delay in G2/M transit. We also discovered that p53 could regulate the expression of multidrug resistance protein-1 (MRP1), a member of the ABC family of transporters that mediates the sensitivity to vinca alkaloids and anthracyclines. We found that as prostate cancer progressed from low stage/low grade to high stage/high grade there was an increased expression of both MRP1 and staining for p53, a surrogate for p53 mutations. We went on to show that p53 regulated the expression of MRP1 and that this produced resistance to doxorubicin and vinblastine. We further demonstrated that MRP1 overexpression blocked the accumulation of flutamide and hydroxy-flutamide (the active metabolite) without affecting transport of dihydrotesterone, thereby blocking access of the anti-androgen but not the androgen to intracellular androgen receptors. Finally, we reviewed the effects of DNA damage on p53 expression and MAP4 repression as a means to increase the effectiveness of breast cancer treatment. These data demonstrated the possibility of individualizing treatment based on p53 status.



___
Source: http://www.hubmed.org/display.cgi?uids=18528466
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: A Scoring System to Predict Nonsentinel Lymph Node Status in Breast Cancer Patients with Metastatic Sentinel Lymph Nodes: A Comparison with Other Scoring Systems.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 7, 2008 at 2:25 AM
Subject: A Scoring System to Predict Nonsentinel Lymph Node Status in Breast Cancer Patients with Metastatic Sentinel Lymph Nodes: A Comparison with Other Scoring Systems.
To: mesothelioma77@gmail.com


[1]Ann Surg Oncol. 2008 Jun 5;
Cho J, Han W, Lee JW, Ko E, Kang SY, Jung SY, Kim EK, Moon WK, Cho N, Park IA, Chung JK, Hwang KT, Kim SW, Noh DY

BACKGROUND: The majority of breast cancer patients with metastatic sentinel lymph node (SLN) do not harbor additional metastasis in non-SLN. It is unclear which patients with metastatic SLN require axillary lymph node dissection (ALND). The aim of this study was to identify predictive factors of non-SLN metastasis and to develop a scoring system. METHODS: The training dataset consisted of 184 breast cancer patients. The independent validation dataset consisted of 82 breast cancer patients. The receiver operating characteristic (ROC) curve was drawn and the area under the ROC curve (AUC) was calculated to assess the discriminative power of the scoring systems. RESULTS: Multivariate analysis revealed that non-SLN status was predicted by preoperative ultrasonographic findings of the axilla, lymphovascular invasion, increasing tumor size, increasing number of metastatic SLN, and decreasing number of nonmetastatic SLN. Based on multivariate logistic regression, we developed a scoring system for predicting non-SLN metastasis. The AUC for our scoring system was superior to other published scoring systems when identical validation data were applied. CONCLUSION: The likelihood of metastatic non-SLN correlated with preoperative ultrasonographic findings of the axilla, increasing pathologic size of the primary tumor, presence of lymphovascular invasion, increasing number of metastatic SLN, and decreasing number of nonmetastatic SLN. Our scoring system appears to be effective and accurate for selecting patients for whom ALND can be avoided.



___
Source: http://www.hubmed.org/display.cgi?uids=18528729
--
 
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 7, 2008 at 2:25 AM
Subject: High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 Jun 5;
de Juan I, Esteban E, Palanca S, Barragán E, Bolufer P

The majority of BRCA1 and BRCA2 mutation detection procedures include screening methods, all of which are time-consuming. High-resolution melting (HRM) is a promising pre-screening method of gene scanning that combines simplicity and rapid identification of genetic variants. We evaluated HRM in the screening of BRCA1/2 Spanish mutations. We studied 40 BRCA1 and 47 BRCA2 DNA samples with different Spanish mutations. We included a group of 20 unknown DNAs from patients with sporadic breast cancer (BC). The assay was performed with the LightCycler((R)) 480 Instrument (Roche). The HRM discriminates all the BRCA1/2 Spanish mutations studied from wild-type DNA. Besides, 54 out of 87 mutations were clearly differentiated from each other. In sporadic BC 11 polymorphisms and three unclassified variants were found in both genes. HRM is a valuable method for rapid screening of BRCA1/2 Spanish mutations and is capable of differentiating new genetic variants in PCR products.



___
Source: http://www.hubmed.org/display.cgi?uids=18528753
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc